Bluejay Diagnostics Completes Warrant Exercises, Clarifies Capital Structure

Bluejay Diagnostics ( (BJDX) ) just unveiled an update.

On February 20, 2026, Bluejay Diagnostics announced that all prefunded warrants issued in its October 2025 private placement had been fully exercised as of February 19, 2026, leaving no prefunded warrants of any class outstanding. Following these exercises, the company reported approximately 972,000 shares of common stock outstanding and disclosed that it still has cash-exercisable warrants for about 1.5 million shares, all with exercise prices of $7.00 or more per share, a development that clarifies its capitalization and potential future equity inflows for investors.

The company also highlighted that several recent Schedule 13G filings do not reflect the 1-for-4 reverse stock split completed on January 29, 2026, which means reported beneficial ownership stakes may appear overstated on a pre-split basis. Bluejay urged investors to account for this discrepancy when interpreting such filings, underscoring the importance of adjusted share counts in assessing ownership levels and market float following its capital structure changes.

The most recent analyst rating on (BJDX) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Bluejay Diagnostics stock, see the BJDX Stock Forecast page.

Spark’s Take on BJDX Stock

According to Spark, TipRanks’ AI Analyst, BJDX is a Neutral.

The score is held down primarily by weak financial performance (no meaningful revenue, sizable losses, and sustained negative free cash flow) despite low debt. Technicals add only modest support with a short-term bounce but a longer-term downtrend. Corporate events are positive for operational progress, but long regulatory/financing timelines and a negative P/E keep overall risk elevated.

To see Spark’s full report on BJDX stock, click here.

More about Bluejay Diagnostics

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes through its Symphony System, a cost-effective, rapid, near-patient testing platform aimed at sepsis triage and monitoring disease progression. The company’s first product candidate, an IL-6 test for sepsis, is designed to deliver results in about 20 minutes from sample to result, but Symphony has not yet received U.S. Food and Drug Administration clearance for marketing as a diagnostic product in the United States.

Average Trading Volume: 101,872

Technical Sentiment Signal: Sell

Current Market Cap: $1.79M

Find detailed analytics on BJDX stock on TipRanks’ Stock Analysis page.